cs-[Pt(NH3);Cl(Creat)] cts-[Pt(NH3)(H20)(Creat)] and cts-Pt(NH3)(Creat)2] were synthesized and the platinum was shown to coordinate to the ring nitrogen, N(3). Human urine samples from patients on cisplatin chemotherapy were shown to contain cisplatin, its hydrolysis product and biotransformation products containing Pt-creatinine, Pt-urea and Pt-udc acid complexes. Urine from carboplatin patients shows fewer biotransformation products. Studies with control and diabetic (protected against cisplatin toxicity) rats showed systematic differences in the biotransformation products formed on administration of cisplatin.
INTRODUCTION
Cisplatin, cis-diamminedichloroplatinum(ll), is one of the most widely used and most successful cancer chemotherapeutic agents (1, 2) . Cisplatin is most effective in the treatment of metastatic testicular tumors, but has been used either alone or in combination protocols for the treatment of a number of other types of tumors (3) . Them is strong evidence to suggest that DNA represents the principal target for cisplatin in the cell (2) , however, the interaction of cisplatin with other biological molecules has been less well studied. The clinical application of cisplatin is accompanied by significant toxicity, of which nephrotoxicity is dose limiting (4) . Although the mechanism of nephrotoxicity is still unknown, the biotransformation products of cisplatin are believed to play a role (5) . A number of "second generation" platinum complexes, such as carboplatin, have been developed in an attempt to overcome the toxicity problems experienced by cisplatin patients (see reference 6 for a review). The observed reduction of toxicity with carboplatin, which may be a function of its lower rate and degree of biotransformation, has resulted in its increasing use in clinical treatment protocols (7) .
Previous studies have identified Pt-methionine complexes in rat plasma after cisplatin treatment (8) . Also, them is evidence suggesting the formation of Pt complexes with cysteine and glutathione in kidney cytosol and urine of rats treated with cisplatin (9) . The reactions of cisplatin with S-containing compounds such as methionine, cysteine and glutathione, have been extensively investigated using HPLC, mass spectrometry (MS) and NMR (10) (11) (12) (13) . However, few Vol. 4,  No. 2, 1997 Determination of Biotran, (14) . Geraldes et al. found that several dimeric Pt-creatinine complexes formed in the 1:1 reaction of cisdiammine-diaquaplatinum(ll) with creatinine (15) . Various products were also obtained when PtX 2 (where X is CI (16, 17) or NO2 (17, 18) ) reacted with creatinine.
Previously we have used HPLC interfaced with inductively coupled plasma mass spectrometry (HPLC-ICP-MS) to investigate various biotransformation products of gold antiarthritis drugs (19) and possible products of cisplatin reactions with sulfur ligands such as cysteine and methionine (20 (10 mm x4.6 mm I.D., 5 im particle size) or a Rainin Dynamax guard column (45 mm x 4.6 mm I.D., 5 particle size) were also used. The two mobile phase systems used throughout the experiments were similar to that described by Zhao et al. (20) . One consisted of 0.1% tdfluoroacetic acid (TFA), 1 FAB-MS Spectra. These spectra were obtained on a VG 30-250 mass spectrometer. 3-Nitrobenzyl alcohol was used as matdx and the spectra were detected using positive ion detection mode. The 1:1 reaction products of cisplatin and creatinine were formed by incubating 0.083 mmol cisplatin and 0.083 mmol creatinine in 10 mL of water for 3 h at 47C. The reaction solution was concentrated by lyophilization and then redissolving in a small volume of water (several IL). The 1:2 reaction products were formed by incubating 0.083 mmol cisplatin with 0.166 mmol creatinine in 2.4 mL of aqueous solution for 24 h at 47C. After incubation, 0.31 mmol LiSO was added to the solution and then ethanol was introduced dropwise until a white precipitate formed. The precipitate was collected by vacuum filtration, washed with methanol and analyzed by mixing the solid with the matrix at the probe tip.
Preparation of Reaction Solutions for HPLC Analysis. The cisplatin hydrolysis products were prepared by incubating 0.001 mmol cisplatin in 5 mL of saline solution (0.9% NaCI) at 37C for 12 hours. Diamminediaquaplatinum(ll) was prepared by incubating 0.005 mmol cisplatin with a stoichiometdc amount of silver nitrate in 5 mL water in absence of light for 12 h at room temperature. The solution was then filtered (0.45 im, Polysulfone) to remove the AgCI precipitate.
The preparation of the 1:1 reaction mixture of cisplatin and creatinine is described above. The reaction products of cisplatin and urea were formed by incubating cisplatin (0.002 mmol) with urea (3.33 mmol) in 10 mL of water for 5 h at 37C. The reaction of cisplatin and uric acid was studied by incubating cisplatin (0.002 mmol) with uric acid (0.018 mmol) in 10 mL of water for 6 h at 37C.
The solutions of platinum complexes were diluted to the desired concentration with mobile phase immediately prior to analysis.
Urine Samples. In some experiments, male Sprague-Dawley rats were injected with cisplatin (5 mg/kg, intravenous) and immediately placed in metabolism cages arranged for collection of fecesfree udne. After collecting for 2 hours, the urine was immediately analyzed. Urine from STZdiabetic as well as normal rats was collected (25) . Human urine specimens were collected from patients receiving cisplatin or carboplatin chemotherapy (26) . The clinical urine samples were either analyzed immediately after collection or divided into 1.5 mL aliquots, flash frozen with liquid nitrogen and stored in the absence of light at-20C. Specimens were thawed rapidly using a method described by Kinoshita (27) . All urine samples were filtered through 0.45 im polysulfone filters and diluted with mobile phase prior to analysis. The mass spectrum of the 1:1 reaction mixture of cisplatin and creatinine is shown in Figure 3 . (31) . Interestingly, these animals, when compared to control rats, are resistant to the kidney damage which accompanies high doses of cisplatin (32) . The mechanism of the protection is not known. We examined urine specimens from both diabetic and control rats injected with cisplatin (5 mg/kg). The HPLC-ICP-MS chromatograms are shown in Figure 6 . The major component is cisplatin, but several other platinum containing species are observed as well. Two of the species show retention times expected for the monoaqua hydrolysis product and the 1:
The identity of the Pt-creatinine complex was confirmed in two ways. First, a similar quantity of the synthetic complex was added to the rat urine specimen. The peak attributed to the complex grew in size but did not change shape, indicating an exact equivalence in retention times between the known complex and that in the rat urine specimen. Second, further evidence for the identity of the 1:1 Pt-creatinine complex in rat udne was provided by separating both the udne sample and the 1:1 reaction mixture of cisplatin and creatinine on a PRP-1 column. The stationary phase of the PRP-1 column is a polystyrene-divinylbezene copolymer. The retention mechanism of the PRP-1 column is based on adsorption, which differs from the partition mechanism of a regular column. Therefore any peak coelution may be tested by chromatographing each of the samples on two different columns. Again, one of the platinum containing species in the rat urine elutes at the J. Dorsey, R. C. Elder, and K. Tepperman
Metal-Based Drugs same retention time as this 1:1 complex, which implies that cis -[Pt(NH)Cl(Creat)] is present. Figure 6a shows the chromatogram of urine from a control rat, whereas that in Figure 6b is from a diabetic rat. In both cases the overall distribution of peaks is quite similar; however, there is an additional peak in Figure 6b (ca. 500 s) which was also present in a urine specimen from a second diabetic rat and missing from the urine specimens of four different control rats treated with cisplatin. The identity of this peak is under study. We currently do not know whether this is a "protective" species. It is clearly a minor component of the total platinum present in urine.
Cisplatin and Its Biotransformation Products in Human Urine. Having identified specific biotransformation products in the urine of rats, we monitored urine samples from a number of cancer patients to determine the platinum species present. Figure 7 shows the platinum species in urine taken from a patient being treated with cisplatin for lung cancer. Under these chromatographic conditions, the diaqua hydrolysis product of cisplatin elutes after 1800 s.
cancer patient. The patient was given 0.5L saline as We have now examined urine hydration therapy (33), followed by a two hour infusion specimens from a number of of cisplatin. LC conditions are as in Figure 5 . Specific different patients, using samples peaks are identified based on retention time. taken immediately after drug infusion or three to four weeks after the initial treatment. Figure  8a shows the HPLC separations of samples from four different patients. The dominant platinum containing species in all cases has the retention time of cisplatin. All samples also contain species with the retention times for the monoaqua hydrolysis product and the 1:1 cisplatin-creatinine complex (R1). As with the rat samples, the identity of R was confirmed by the addition of the 1:1 reaction mixture to the udne specimen. The peak at approximately 800 s increased in height but did not change in shape.
We have also analyzed the udne of patients approximately three weeks after one dose (immediately prior to the next dose). In these patients, them is still a significant amount of platinum present. Platinum levels immediately after treatment are typically in the 30-50 ppm range, while after three weeks, levels are in the 50-100 ppb range. Carboplatin in Human Urine. We have begun to use HPLC-ICP-MS to study carboplatin and its biotransformation in patient samples. The HPLC separations of urine from three patients are shown in Figure 9 . Specimens analyzed in the left panel were taken immediately following the carboplatin treatment. The right panel shows analyses of urine from the same patients three weeks after treatment. In all three samples immediately after treatment, the main platinum species present is carboplatin. In one of the patients, there is an additional platinum species present, which is not retained by the column. A minor platinum peak is also present in all the samples at approximately 375 s. None of these species correspond to those observed in the urine of the cisplatin patients. In the urine samples collected three weeks after the dose, there is still significant platinum present (150-275 ppb). By this point, significant biotransformation has occurred. Interestingly, in one of the patients, Patient 5, there are platinum species present which have the retention times for cisplatin and the monoaqua hydrolysis product. This result provides evidence that carboplatin can be converted in vivo to cisplatin, followed by hydrolysis and presumably other subsequent reactions characteristic of administered cisplatin. that cisplatin-glutathione products are formed in the body (9) . By using HPLC analysis coupled with ICP-MS to provide platinum specific detection, we have shown that a large number of biotransformation products can be formed as a result of in vitro reactions with nitrogenous ligands such as creatinine, urea and uric acid. Some of these reaction products are detectable in the urine of patients undergoing cisplatin chemotherapy. Comparison of the chromatograms from samples taken immediately after therapy with those taken weeks later indicates that significant biotransformation continues to occur. In a single individual, the chromatograms taken at different times are qualitatively similar, but there are quantitative differences. Comparison of samples from different individuals reveals some qualitative differences as well.
Comparison of the samples from cisplatin and carboplatin patients illustrates significant differences between the two drugs. The samples from carboplatin patients taken immediately after treatment show fewer biotransformation products, with carboplatin itself being the principal platinum species present. This observation is likely the result of the "relative stability" of the leaving groups of the two compounds (6) . Essentially all the Pt detectable by flow injection is recovered on the chromatographic column. The pdmary metabolite identified in rat urine, a ringopened adduct of carboplatin-methionine (34) is not present in these patients. The cationic methionine complex should elute after the carboplatin under these chromatographic conditions. In
